John F. Paolini Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

John F. Paolini is CHIEF MEDICAL OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 61,324 shares of KNSA, which is worth approximately $2.47 Million. The most recent transaction as insider was on Apr 08, 2024, when has been sold 2,497 shares (Class A Common Share) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 61.3K

0% 3M change

17.84% 12M change

Total Value Held $2.47 Million

John F. Paolini Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 08 2024	BUY Exercise of conversion of derivative security	-	2,497 Added 4.89%	48,536 Class A Common Share
Apr 01 2024	SELL Payment of exercise price or tax liability	$9,396 $19.7 p/Share	477 Reduced 1.03%	46,039 Class A Common Share
Apr 01 2024	BUY Exercise of conversion of derivative security	-	1,624 Added 3.37%	46,516 Class A Common Share
Mar 01 2024	SELL Open market or private sale	$410,233 $21.77 p/Share	18,844 Reduced 29.57%	44,892 Class A Common Share
Mar 01 2024	BUY Exercise of conversion of derivative security	$35,049 $1.86 p/Share	18,844 Added 23.1%	62,736 Class A Common Share
Feb 27 2024	SELL Open market or private sale	$213,580 $21.03 p/Share	10,156 Reduced 18.45%	44,892 Class A Common Share
Feb 27 2024	BUY Exercise of conversion of derivative security	$18,890 $1.86 p/Share	10,156 Added 15.58%	55,048 Class A Common Share

Dec 07 2023	SELL Open market or private sale	$505,934 $17.69 p/Share	28,600 Reduced 38.92%	44,892 Class A Common Share
Dec 07 2023	BUY Exercise of conversion of derivative security	$53,196 $1.86 p/Share	28,600 Added 28.01%	73,492 Class A Common Share
Sep 05 2023	SELL Open market or private sale	$7,012 $17.53 p/Share	400 Reduced 0.88%	44,892 Class A Common Share
Sep 05 2023	BUY Exercise of conversion of derivative security	$744 $1.86 p/Share	400 Added 0.88%	45,292 Class A Common Share
Sep 02 2023	SELL Payment of exercise price or tax liability	$9,004 $17.76 p/Share	507 Reduced 1.12%	44,892 Class A Common Share
Sep 02 2023	BUY Exercise of conversion of derivative security	-	1,725 Added 3.66%	45,399 Class A Common Share
Sep 01 2023	SELL Payment of exercise price or tax liability	$13,035 $17.76 p/Share	734 Reduced 1.65%	43,674 Class A Common Share
Sep 01 2023	BUY Exercise of conversion of derivative security	-	2,498 Added 5.33%	44,408 Class A Common Share
Jul 25 2023	SELL Open market or private sale	$550,420 $18.98 p/Share	29,000 Reduced 40.9%	41,910 Class A Common Share
Jul 25 2023	BUY Exercise of conversion of derivative security	$53,940 $1.86 p/Share	29,000 Added 29.03%	70,910 Class A Common Share
Apr 10 2023	SELL Payment of exercise price or tax liability	$7,861 $10.71 p/Share	734 Reduced 1.72%	41,910 Class A Common Share
Apr 10 2023	BUY Exercise of conversion of derivative security	-	2,498 Added 5.53%	42,644 Class A Common Share
Mar 20 2023	SELL Payment of exercise price or tax liability	$11,987 $11.12 p/Share	1,078 Reduced 2.61%	40,146 Class A Common Share
Mar 20 2023	BUY Exercise of conversion of derivative security	-	3,671 Added 8.18%	41,224 Class A Common Share
Mar 16 2023	SELL Payment of exercise price or tax liability	$5,810 $11.46 p/Share	507 Reduced 1.33%	37,553 Class A Common Share
Mar 16 2023	BUY Exercise of conversion of derivative security	-	1,725 Added 4.34%	38,060 Class A Common Share
Nov 07 2022	SELL Open market or private sale	$430,459 $15.18 p/Share	28,357 Reduced 43.83%	36,335 Class A Common Share
Nov 07 2022	BUY Exercise of conversion of derivative security	$52,744 $1.86 p/Share	28,357 Added 30.48%	64,692 Class A Common Share

JFP

John F. Paolini

CHIEF MEDICAL OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account